Immunotherapy 2018

DESCRIPTION

On 12 & 13 November 2018, Dublin (Ireland) will host the BioTech Pharma Summit: Immunotherapy 2018 conference. This year’s event will bring together established Pharma & Biotech thought-leaders, top academics and researchers, and a collection of emerging scientists exploring next-generation breakthroughs in the burgeoning area of cancer immunotherapy.

Immunotherapy 2018 will bring together the full community at a single meeting point to provide excitement and opportunity for the whole value chain.

Immunotherapy is the brightest hope and a cornerstone in the next generation fight against cancer. Novel discoveries in checkpoint inhibitors have enabled stunning breakthroughs and generated high optimism for the sector, including exciting new customizations in form of CAR -T and Oncolytic Viral Immunotherapy.

If you’re involved in the pharma, biotech, government, or academic sector looking toward commercialization and development of immunotherapies, this is an event you cannot afford to miss.

 

The BioTech Pharma Summit: Immunotherapy 2018 helps to address the gaps in knowledge of how and when to combine therapies, and how to integrate immunotherapy into current standard-of-care or novel targeted therapy approaches – both preclinical and clinical.

 
KEY PRACTICAL LEARNING POINTS

  • Advanced methods, technological developments and strategies in Cancer Immunotherapy
  • The success of antibodies in therapeutics and engineering
  • Rational Immunotherapy Combinations: Preclinical Models as Predictive or Responses
  • The true potential of the next generation immune checkpoint pathways
  • Immuno-oncology: current and future advances
  • A harmonized approach to biomarker data management
  • Overcoming T Cell Exclusion and an Immune-Privileged Microenvironment with Combination Approaches
  • Revolutionary cancer treatment with personalised cancer vaccines
  • Reinforcing anti-tumour immunity
  • Combining Checkpoint Inhibitors with Targeted Therapies
  • Biomarkers and Patient Selection Strategies for Immunotherapy Combination
  • Managing unique immune-mediated adverse reactions and toxicity effects
  • Progressive genetic engineering techniques
  • Vaccines, Oncolytic Viruses and Cellular Therapies
  • Preclinical and clinical progress in Cancer Immunotherapy
  • CAR T-Cell Therapy: A game changer in cancer treatment
  • Regulatory aspects of the EU/US

WHO SHOULD ATTEND?

The BioTech Pharma Summit (EPM Group) are exclusive events consisting of world-class keynote addresses and presentations designed specifically for senior level attendees from research & academic institutions, clinical research institutions and hospital laboratories as well as major pharmaceutical and biotech companies based Worldwide. Delegates typically include CEOs, VPs, Drug developers, Academics and Researchers, CROs, Scientists and Medical Doctors of:

  • Oncology
  • Clinical Diagnostics
  • Drug Discovery
  • Drug Delivery
  • Antibody Engineering
  • Antibody Discovery
  • Cancer Immunotherapy
  • Immuno-Oncology
  • Hematology
  • Bioinformatics
  • Cancer Genomics
  • Infection and Immunity
  • Cell Therapy Research
  • Pathology
  • Cell & Gene Therapy
  • Preclinical Development
  • Tumour Immunology
  • Vaccines Development
  • Translational Medicine Genetics and Genomics
Basic Package
1,995
Buy Ticket

Access to all Sessions

Access to all Networking Sessions

Cocktail Reception Included

Premium Package
3,550
Buy Ticket

Unique one-on-one meetings

Airport pick-up/drop-off

2 nights at the Hotel Venue

Basic Exhibition Package
3,550
Buy Ticket

3m2 exhibition space

1 Complementary ticket

25% discount for extra ticket

Premium Exhibition Package
6,995
Buy Ticket

6m2 exhibition space

1 Complementary ticket

2 nights at the Hotel Venue